Variable | ADT | No ADT | Total | p-value | no ADT | p-value |
---|---|---|---|---|---|---|
(cases) | (unmatched controls) | (unmatched) | (matched controls) | (matched) | ||
n = 421 | n = 797 | n = 1218 | n = 421 | |||
Mean age | 68.63 | 68.5 | 0.75 | 68.4 | 0.67 | |
Mean PSA | 8.47 | 8.18 | 0.28 | 8.12 | 0.252 | |
Gleason Score (mean) | 6.9 | 6.38 | <0.001 | 6.83 | 0.99 | |
Race | <0.001 | 0.042 | ||||
White | 278 (11.7%) | 650 (81.6) | 928 | 313 (74.3%) | ||
Black | 79 (18.8%) | 96 (12%) | 175 | 67 (15.9%) | ||
Hispanic | 44 (10.4%) | 34 (4.3%) | 78 | 27 (6.4%) | ||
Other | 20 (4.8%) | 17 (2.1%) | 37 | 14 (3.3%) | ||
Year of diagnosis (mean) | 2003 | 1997 | <0.001 | 2001 | <0.001 | |
Dose of radiation | <0.001 | |||||
Low ≤ 70 | 28 (6.6%) | 390 (49.8%) | 418 | 71 (16.9%) | <0.001 | |
High > 70 | 393 (93.3%) | 407 (51.1%) | 800 | 350 (8.3%) | ||
Clinical T-stage | 0.27 | 0.47 | ||||
T1 | 205 (48.7%) | 336 (42.2%) | 571 | 234 (55.6%) | ||
T2a | 94 (22.3%) | 164 (20.1%) | 258 | 95 (22.6%) | ||
T2b,c | 122 (30%) | 267 (33.5%) | 389 | 92 (21.8%) | ||
Length of concurrent hormones* | ||||||
Short (≤6 months) | 271 (64.4%) | 271 | ||||
Long (>6 months) | 150 (35.6%) | 150 | ||||
Timing of hormones | ||||||
Neoadjuvant | 371 (88.1%) | 371 | ||||
Adjuvant | 50 (11.9%) | 50 | ||||
Salvage | 8 (1.9%) | 114 (14.3%) | 122 | <0.001 | 40 (9.5%) | <0.001 |
Radiation type< | <0.001 | |||||
3-D conformal | 73 (17.3%) | 546 (68.5%) | 619 | <0.001 | 171 (40.6%) | |
IMRT | 348 (82.7%) | 251 (31.5%) | 599 | 250 (59.4%) |